Top ▲
Gene and Protein Information | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | - | 277 | 4q35.1 | CASP3 | caspase 3 | |
Mouse | - | 277 | 8 26.39 cM | Casp3 | caspase 3 | |
Rat | - | 277 | 16q11 | Casp3 | caspase 3 |
Database Links | |
Specialist databases | |
MEROPS | C14.003 (Hs) |
Other databases | |
Alphafold | P42574 (Hs), P70677 (Mm), P55213 (Rn) |
BRENDA | 3.4.22.56 |
ChEMBL Target | CHEMBL2334 (Hs), CHEMBL5632 (Mm), CHEMBL1075185 (Rn) |
Ensembl Gene | ENSG00000164305 (Hs), ENSMUSG00000031628 (Mm), ENSRNOG00000010475 (Rn) |
Entrez Gene | 836 (Hs), 12367 (Mm), 25402 (Rn) |
Human Protein Atlas | ENSG00000164305 (Hs) |
KEGG Enzyme | 3.4.22.56 |
KEGG Gene | hsa:836 (Hs), mmu:12367 (Mm), rno:25402 (Rn) |
OMIM | 600636 (Hs) |
Pharos | P42574 (Hs) |
RefSeq Nucleotide | NM_004346 (Hs), NM_032991 (Hs), NM_009810 (Mm), NM_012922 (Rn) |
RefSeq Protein | NP_004337 (Hs), NP_116786 (Hs), NP_033940 (Mm), NP_037054 (Rn) |
UniProtKB | P42574 (Hs), P70677 (Mm), P55213 (Rn) |
Wikipedia | CASP3 (Hs) |
Enzyme Reaction | ||||
|
Substrates and Reaction Kinetics | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Endogenous activators (Human) |
Caspase 8, caspase 9, caspase 10, GrB |
Download all structure-activity data for this target as a CSV file
Activators | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Inhibitors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Immunopharmacology Comments |
Defective caspase 3 expression in immune effector cells may influence susceptibility to Kawasaki disease, an acute vasculitis syndrome affecting small- and medium-sized arteries of infants and children [7]. |
Immuno Process Associations | ||
|
||
|
||
|
||
|
||
|
||
|
||
|
Immuno Disease Associations | ||||||||||
|
1. Brockstedt E, Rickers A, Kostka S, Laubersheimer A, Dörken B, Wittmann-Liebold B, Bommert K, Otto A. (1998) Identification of apoptosis-associated proteins in a human Burkitt lymphoma cell line. Cleavage of heterogeneous nuclear ribonucleoprotein A1 by caspase 3. J Biol Chem, 273 (43): 28057-64. [PMID:9774422]
2. Choong IC, Lew W, Lee D, Pham P, Burdett MT, Lam JW, Wiesmann C, Luong TN, Fahr B, DeLano WL et al.. (2002) Identification of potent and selective small-molecule inhibitors of caspase-3 through the use of extended tethering and structure-based drug design. J Med Chem, 45 (23): 5005-22. [PMID:12408711]
3. Han Y, Giroux A, Colucci J, Bayly CI, Mckay DJ, Roy S, Xanthoudakis S, Vaillancourt J, Rasper DM, Tam J et al.. (2005) Novel pyrazinone mono-amides as potent and reversible caspase-3 inhibitors. Bioorg Med Chem Lett, 15 (4): 1173-80. [PMID:15686936]
4. Izban KF, Ergin M, Huang Q, Qin JZ, Martinez RL, Schnitzer B, Ni H, Nickoloff BJ, Alkan S. (2001) Characterization of NF-kappaB expression in Hodgkin's disease: inhibition of constitutively expressed NF-kappaB results in spontaneous caspase-independent apoptosis in Hodgkin and Reed-Sternberg cells. Mod Pathol, 14 (4): 297-310. [PMID:11301346]
5. Jiang X, Kim HE, Shu H, Zhao Y, Zhang H, Kofron J, Donnelly J, Burns D, Ng SC, Rosenberg S et al.. (2003) Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway. Science, 299 (5604): 223-6. [PMID:12522243]
6. Newton AS, Glória PM, Gonçalves LM, dos Santos DJ, Moreira R, Guedes RC, Santos MM. (2010) Synthesis and evaluation of vinyl sulfones as caspase-3 inhibitors. A structure-activity study. Eur J Med Chem, 45 (9): 3858-63. [PMID:20541849]
7. Onouchi Y, Ozaki K, Buns JC, Shimizu C, Hamada H, Honda T, Terai M, Honda A, Takeuchi T, Shibuta S et al.. (2010) Common variants in CASP3 confer susceptibility to Kawasaki disease. Hum Mol Genet, 19 (14): 2898-906. [PMID:20423928]
8. Putt KS, Chen GW, Pearson JM, Sandhorst JS, Hoagland MS, Kwon JT, Hwang SK, Jin H, Churchwell MI, Cho MH et al.. (2006) Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy. Nat Chem Biol, 2 (10): 543-50. [PMID:16936720]
9. Scott CW, Sobotka-Briner C, Wilkins DE, Jacobs RT, Folmer JJ, Frazee WJ, Bhat RV, Ghanekar SV, Aharony D. (2003) Novel small molecule inhibitors of caspase-3 block cellular and biochemical features of apoptosis. J Pharmacol Exp Ther, 304 (1): 433-40. [PMID:12490620]
C14: Caspase: Caspase 3. Last modified on 25/09/2018. Accessed on 02/11/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetoimmunopharmacology.org/GRAC/ObjectDisplayForward?objectId=1619.